To compare the efficacy, nephrotoxicity, and ototoxicity of once-daily dosing of aminoglycosides versus conventional dosing.
Design:
Meta-analysis of 14 randomized trials identified through a MEDLINE search (January 1965-May 1996).
Patients:
Neutropenic and nonneutropenic adults.
Interventions:
Patients were randomly selected to receive an aminoglycoside once daily or in multiple daily doses.
Measurements and Main Outcomes:
The outcomes considered were clinical cure, bacteriologic cure, nephrotoxicity, auditory toxicity, and vestibular toxicity. The data were analyzed in the following subgroups: (1) all trials, (2) nonneutropenic patients, (3) neutropenic patients, and (4) patients with undefined neutrophil status. For all trials the pooled risk ratio was 1.268 (95% CI 0.828 to 1.939) for clinical cure, and was 1.390 (95% CI 1.350 to 1.392) for bacteriologic cure. Nephrotoxicity had a pooled risk ratio of 0.765 (95% CI 0.468 to 1.252), that for auditory toxicity was 1.117 (95% CI 0.151 to 5.636), and that for vestibular toxicity was 1.155 (95% CI 0.221 to 6.039). Analysis of the subgroups, including a separate analysis of neutropenic patients, demonstrated similar results.
Conclusions:
When all trials were considered, once-daily administration of aminoglycosides had similar efficacy and no increase in nephrotoxicity or ototoxicity compared with conventional aminoglycoside dosing.
Get full access to this article
View all access options for this article.
References
1.
EdsonRSTerrellCL. The aminoglycosides. Mayo Clin Proc1991; 66: 1158–64.
2.
BatesRDNahataMC. Once-daily administration of aminoglycosides. Ann Pharmacother1994; 28: 757–66.
3.
ZaskeDE. Aminoglycosides. In: EvansWESchentagJJJuskoWJ, eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring. 3rd ed.Vancouver, WA: Applied Therapeutics, 1992: 14-1–14-47.
4.
MattieHCraigWAPechereJC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother1989; 24: 281–93.
5.
FrenchMACerraFBPlautMESchentagJJ. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother1981; 19: 147–52.
6.
KapusnikJEHackbarthCJChambersHFCarpenterTSandeMA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis1988; 158: 7–12.
7.
GerberAUFeller-SegessenmannC. In vivo assessment of in vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother1985; 15: 201–6.
8.
MacArthurRDLolanVZarFAJacksonGG. Biphasic, concentration dependent and rate limited concentration independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis1984; 150: 778–9.
9.
NicolauDPFreemanCDBelliveauPPNightingaleCHRossJWQuintilianiR. Experience with a once daily aminoglycoside administered to 2184 adult patients. Antimicrob Agents Chemother1995; 59: 650–6.
GerberAU. Comparison of once daily versus thrice daily human equivalent dosing of aminoglycosides: Basic considerations and experimental approach. J Drug Dev1988; 1 (suppl 3):17–23.
12.
JacksonGGLolansVTDaikosGL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotic with implications for dosing. J Infect Dis1990; 162: 408–13.
13.
KarlowskyJAZhanelGGDavidsonRJHobanDJ. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother1994; 33: 937–47.
14.
DaikosGLJacksonGGLolansVTLivermoreDM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis1990; 162: 414–20.
15.
TulkensPM. Pharmacokinetics and toxicological evaluation of a once daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother1991; 27 (suppl C):49–61.
16.
ter BraakEWDeVriesPJBouterKPVanDerVegtSGDorresteinGCNortierJW. Once daily dosing regimen for aminoglycosides plus β-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med1990; 89: 58–66.
17.
PrinsJMBullerHRKuijperEJTangeRASpeelmanP. Once versus thrice daily gentamicin in patients with serious infections. Lancet1993; 341: 335–9.
18.
VerpootenGAGiulianoRAVerbistLEestermansGDeVroeME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther1989; 45: 22–7.
19.
BrummettREFoxKE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother1989; 33: 797–800.
20.
Ba HuyP TranBernardPSchachtJ. Kinetics of gentamicin uptake and release in the rat: Comparison of inner ear tissues and fluids with other organs. J Clin Invest1986; 77: 1492–500.
21.
RaikumarS VincentKooJM. Once daily aminoglycoside dosing (letter). Lancet1993; 341: 895.
22.
ShumockGTRaberSRCrawfordSYNadererOJRodvoldKA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy1995; 15: 201–9.
23.
PetittiDB. Statistical methods in meta-analysis and other statistical issues in meta-analysis. In: Meta-analysis, decision analysis, and cost-effectiveness analysis. New York: Oxford University Press, 1994: 90–130.
24.
FanSTLauWYTeoh-ChanCHLauKFMauracherEH. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother1988; 22: 69–74.
25.
HollenderLFBahniniJDe ManziniNLauWYFanSTHermansyurK, A multicenter study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother1989; 23: 773–83.
26.
MarikPELipmanJKobilskiSScribanteJ. A prospective randomized study comparing once versus twice daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother1991; 28: 753–64.
27.
RazRAdawiMRomanoS. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis1995; 14: 88–91.
28.
SturmAW. Netilmicin in the treatment of gram negative bacteremia: Single daily versus multiple daily dosage. J Infect Dis1989; 159: 931–7.
29.
MallerRIsakssonBNilssonLSorenL. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother1988; 22: 75–9.
30.
MallerREmanuelssonBMIsakssonBNilssonL. Amikacin once daily: A new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis1990; 22: 575–9.
31.
da CostaP MendesKaufmanL. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology1992; 39: 350–4.
32.
BeaucaireGLeroyOBeuscartCKarpPChidiacCCaillauxM, Clinical and bacteriological efficacy and practical aspects of amikacin given once daily for severe infection. J Antimicrob Chemother1991; 27 (suppl C):91–103.
33.
MartinoPGirmeniaCRaccahRMicozziACiminoGMandelliF. Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients. Haematologica1990; 75: 69–74.
34.
MeunierFVan der AuweraPAnounMIbrahimSTulkensPM. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: A pilot study. J Antimicrob Chemother1991; 27 (suppl C):129–39.
35.
PrinsJMBullerHRKuijperEJTangeRASpeelmanP. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections — A randomized clinical trial. J Antimicrob Chemother1994; 33: 823–35.
36.
MallerRAhmeHEilardTErikssonI, Lausen I, for the Scandinavian Amikacin Once Daily Study Group. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother1991; 27 (suppl C):121–8.
37.
CohenBSaginurRClecnerBMendelsonJKavalecE. Double-blind comparative trial of once versus twice-daily netilmicin therapy in severe acute urinary tract infections. Curr Ther Res1985; 38: 880–4.
38.
KlasterskyJPrevostJMMeunier-CarpentierFDaneauDGerardM. Comparative trial in single-dose versus twice daily sisomicin in bacteriuric patients. J Clin Pharmacol1977; 17: 520–8.
Van der AuweraPMeunierFIbrahimSKaufmanLDerdeMPTulkensPM. Pharmacodynamic parameters and toxicity of netilmicin (6 mg/kg/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother1991; 35: 640–7.
41.
RossettiSR. Single shot versus conventional therapy with amikacin for treatment of uncomplicated urinary tract infection: A multi-center study. Chemotherapia1986; 5: 394–9.
42.
LandesRR. Single daily doses of tobramycin in therapy of urinary tract infections. J Infect Dis1976; 134 (suppl):S142–5.
43.
ViganoAPrincipiNBrivioLTommasiPStasiPVillaAD. Comparison of 5 milligrams of netilmicin per kilogram of body weight versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother1992; 36: 1499–503.
44.
TrujilloHRobledoJRobledoCEspinalDGarcesGMejiaJ, Single daily dose amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother1991; 27 (suppl C):141–7.
45.
KafetzisDASianidouLVlachosEDavrosJBatramisT. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infection. J Antimicrob Chemother1991; 27 (suppl C):105–12.
46.
ViscoliCDudleyMFerreaGBoniLCastagnolaEVarrettaMA, Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother1991; 27 (suppl C):102–20.
47.
ElhananKSiplovichLRazR. Gentamicin once daily versus thrice daily in children. J Antimicrob Chemother1995; 35: 327–32.
48.
ShankarASharmaSD. Gentamicin as once daily dose therapy in recurrent urinary tract infections in children. Curr Ther Res1987; 41: 599–603.
49.
LanghendriesJPBattistiOBertrandJMFrancoisADarimontJIbrahimS, Once a day administration of amikacin in neonates: Assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther1993; 20: 220–30.
50.
WagnerBPPfeningerJ. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Intensive Care Med1994; 20: 365–7.
51.
PrincipiNGervasoniARealiETagliabueP. Treatment of urinary tract infections in children with a single daily dose of gentamicin. Helv Pediatr Acta1977; 32: 343–50.
52.
WallenLZellerWPGoesslerMConnorEYogevR. Single dose amikacin treatment of first childhood E. coli UTI. J Pediatr1983; 103: 316–9.
53.
GonzalezPAguadoJMMartinMAFernandez-ChaconTOrtunoB. Once daily aminoglycoside dosing (letter). Lancet1993; 341: 895.
54.
deVriesPJVerkooyenPLeguitPVerbrughHA. Prospective randomized study of once daily versus thrice daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis1990; 9: 161–8.
55.
GiamarellouHYiallourosKPetrikkosEMoschovakisEVavousakiE. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother1991; 27: 73–9.
56.
MallerRAhmeHHolmenCLausenINilssonLESmedjegardJ, For the Scandinavian Amikacin Once Daily Study Group. Once versus twice daily amikacin regimen efficacy and safety in systemic gram negative infections. J Antimicrob Chemother1993; 31: 939–48.
57.
VanhaeverbeekMSiskaGDouchampsJHerchuelzA. Comparison of the efficacy and safety of amikacin once or twice a day in the treatment of severe gram negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol1993; 31: 153–6.
58.
International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med1993; 119: 584–93.
59.
GibsonJJohnsonLSnowdownLJoshuaDYoungGMacLeodC, Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: A randomized trial. Int J Hematol1993; 58: 63–72.
60.
HansenMAchenFCarstensenCCoolidgeJDahlagerJFrimodt-MollerN, Once-versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: A randomized, controlled study of efficacy and safety. J Drug Dev1988; 1: 119–24.
61.
RozdzinskiEKernWVReichleAMoritzTSchmeiserTGausW, Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical antibiotics as empirical therapy for febrile neutropenia patients. J Antimicrob Chemother1993; 31: 585–98.
62.
MauracherEHLauWYKarowisatroHOngKHGenatoVX. Comparison of once daily and thrice daily netilmicin regimens in serious systemic infections: A multicenter study in six Asian countries. Clin Ther1989; 11: 604–13.
63.
MuijskenMVreedeRVan DijkWHaverkornMJKaufmanLDerdeMP. A randomized clinical study of efficacy and safety of once daily versus conventional dosing of netilmicin in patients with severe infections. J Drug Dev1988; 1 (suppl 3):145–6.
64.
NordstromLRingbergHCronbergSTjernstormOWalderM. Does administration of aminoglycoside in single daily dose affect its efficacy and toxicity?J Antimicrob Chemother1990; 25: 159–73.
65.
MarikPELipmanJKobilskiSScribanteJ. A prospective randomized study comparing once versus twice daily amikacin dosing in critically ill adults and paediatric patients. J Antimicrob Chemother1991; 28: 753–64.
66.
GalloeAMGraudalNChristensenHRKampmannJP. Aminoglycoside: Single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol1995; 48: 39–43.
67.
HatalaRDinhTCookDJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med1996; 124: 717–25.
68.
Ferriols-LisartRAlos-AlminhanaM. Effectiveness and safety of once-daily aminoglycoside: A meta-analysis. Am J Health-Syst Pharm1996; 53: 1141–50.
69.
BarzaMCappellariJCLauJ. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ1996; 312: 338–45.
70.
MunckhofWJGraysonMLTunridgeJD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother1996; 37: 645–63.
71.
FreemanCDStrayerAH. Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on once daily aminoglycoside comparative trials. Pharmacotherapy1996; 16: 1093–102.
72.
EinarsonTRLeederJSKorenG. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm1988; 22: 813–24.
73.
SacksHSBerrierJReitmanDAncona-BerkVAChalmersTC. Meta-analyses of randomized controlled trials. N Engl J Med1987; 316: 450–5.
74.
GlassGV. Integrating findings: The meta-analysis of research. Rev Res Educ1978; 5: 351–79.
